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analysis (2), although other authorities recommend the need for
summary measures for the best estimate of the impact of an
intervention, albeit that correct methodological techniques are
used to investigate the differences among single trials (3).
Furthermore, Moreno et al. (1) tried to assess, by means of
linear regression analysis, the possible association of several angio-
graphic variables with the benefit of stents, finding a significant
inverse relationship between reference vessel diameter (RVD) and
the risk reduction of angiographic restenosis after stent placement
with respect to balloon angioplasty (i.e., the smaller the vessel, the
larger the benefit of stenting). However, we believe the correct
methodological tool to address whether a covariable may have a
significant effect on the outcome in a meta-analysis is meta-
regression (4). Using this technique (which weights each study
according to its statistical weight [i.e., the inverse of the variance])
to analyze the very same data presented in their study, we did not
find any significant relation between RVD and risk reduction of
angiographic restenosis after stent placement.
Moreover, another recent trial, published only as an abstract (5),
did not confirm the investigators’ hypothesis. Indeed, in front of
the smallest mean RVD of all the trials on small-vessel disease
(2.17 mm), there was a nonsignificantly increased risk of restenosis
(relative risk 1.14 [95% confidence interval 0.89 to 1.48]) after
stenting.
Finally, meta-analytic techniques allow quantitative assessment
of treatment effects from pooled data. With the widening of their
use and because of potential errors, improper analyses may result in
misleading conclusions; thus, optimal methodological procedures
should be utilized to validate findings.
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REPLY
We acknowledge Dr. Agostoni and colleagues for their interest in
our work, but we do not agree with their comments. Heterogeneity
between studies is not a contraindication to quantitative pooling
analysis. When analyzing the effect of a therapeutic mean, two
different types of analysis can be performed: random-effect model
(between-trial variance and within-trial variance) and fixed-effect
model (1,2). The first type is used when significant heterogeneity
exists, whereas the fixed-effect model assumes that between-trial
variance is zero. As we clearly specified in our Methods, we used
the random-effect model (3). As Agostoni and colleagues empha-
size, controversy abounds concerning the best approach when
heterogeneity exists, but we believe the investigators consider this
methodology correct. In fact, in a very recently published meta-
analysis, they concluded that radial access yields to lower proce-
dural success than does femoral access, despite having found
significant heterogeneity between studies when evaluating this end
point (4).
Also, it is important to consider the causes of heterogeneity
among trials. In our study, heterogeneity was not due to clinical or
design discrepancies between the studies, but rather to differences
in the number of patients included (treatment favored balloon only
in the COMPASS trial (5) and in the study by Park et al. (6), and
these had the lowest number of patients).
The second criticism raised by Agostoni and colleagues is that
the relationship between risk ratio for restenosis and reference
vessel diameter (RVD) should have been adjusted by the inverse of
variance. Apparently they were unable to find (data not provided)
any significant relation between both variables. Accordingly, we
have analyzed our data after adjusting this relation for the inverse
of variance (7–9). After analyzing it, the association between RVD
and risk reduction remained significant, and in fact the beta-
coefficient for RVD was even higher (Y6.514 2.674 [RVD]
 2.156 [varRR]); p value for RVD  0.017).
Moreover, ever since we wrote up the study, several randomized
trials comparing stent and balloon in small vessels have been
reported and even published (10–12). Dr. Agostoni and colleagues
only mention the recently reported ISAR SMART-2 trial, in
which coronary stenting was nonsuperior to balloon in small
coronary vessels. The ISAR–SMART-2, however, has one impor-
tant limitation not recognized by Agostoni et al: the very high rate
of cross-over from balloon to stent (40%, in comparison with
19% in our meta-analysis) (10). Unfortunately, they do not
mention the already published study by Kinsara et al. (12), in
which restenosis rate decreased from 49% to 30% (balloon and
stent, respectively; p 0.009) in very small vessels (2.09 mm). The
same occurs with the LASMAL-II trial, in which angiographic
restenosis significantly decreased from 45% to 28%, respectively (p
 0.043) (11).
Interventional cardiology is one of the areas of medicine in
which most randomized trials are being performed. Because of
that, we may be tempted to use meta-analytic techniques without
profound knowledge of the trials included and the methodologies
employed. To avoid improper conclusions, it is necessary to
understand adequately the meta-analytic techniques and their
limitations, to obtain advice from expert statisticians, and to
evaluate thoroughly all the trials included. This methodology
allowed us to conclude that coronary stenting reduces the reste-
nosis rate in comparison to balloon angioplasty in small coronary
arteries (3).
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Thrombolysis Should Be
Regarded as First-Line Therapy
for Prosthetic Valve Thrombosis
in the Absence of Contraindications
I read with great interest the retrospective, multicentric Prostethic
Valve Thrombolysis-Role of Transesophageal Echocardiography
(PRO-TEE) study in a recent issue of the Journal (1). The results
of the registry appear to confirm our previous and rather conser-
vative recommendations (2). According to these guidelines ob-
structive thrombi in patients presenting in NYHA functional class
III to IV should be treated with thrombolysis if the surgical risk is
high. However, the basis of these recommendations was an
international consensus conference held in 1994, when thrombol-
ysis of left-sided prosthetic valves was a rather debated approach.
A review of 53 studies cited in the published reports indicates the
results of thrombolysis being inferior in the period between 1974
and 1995 than between 1996 and 2003: success rate 77% versus
90%, embolism rate 13% versus 4%, death rate 7.5% versus 2.5%,
while the number of treated episodes was virtually the same (235
vs. 234). Recent reports and reviews recommend thrombolysis as
the first-line approach in the management of prosthetic valve
thrombosis irrespective of functional class or thrombus size (3–5).
In contrast, contributors to the registry conclude that throm-
bolysis should be limited to patients with thrombus size 0.8 cm2
as measured by transesophageal echocardiography (TEE). This
conclusion was based on a small number of patients coming from
14 centers over 16 years. The selection of patients into the registry
may have been biased (1). Moreover, in obstructive cases the fixed
thrombus usually cannot be measured within the valve orifice (3,4).
In contrast, mobile nonobstructive thrombi are easily measur-
able and in most cases large, at least in length, but thrombolysis of
these thrombi can be performed with negligible embolic risk (3–5).
The role of TEE is particularly essential to reveal thrombus in
nonobstructive cases (3) and serial TEE is required to monitor the
efficacy of thrombolysis (4,6). Assessment of “hemodynamic” and
“clinical results” without “thrombolytic results” does not allow the
evaluation of treatment results in nonobstructive cases. In sum-
mary, despite our previous recommendations I consider use of
thrombolysis in all patients with prosthetic valve thrombosis
irrespective of functional class and thrombus size unless contrain-
dications exist. Thus, TEE must be performed before and during
treatment.
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